✦ LIBER ✦

Canalicular stenosis secondary to weekly versus every-3-weeks docetaxel in patients with metastatic breast cancer

✍ Scribed by Bita Esmaeli; Gabriel N Hortobagyi; Francisco J Esteva; Daniel Booser; M.Amir Ahmadi; Edgardo Rivera; Rebecca Arbuckle; Ebrahim Delpassand; Laura Guerra; Vicente Valero

Book ID: 117327753
Publisher: Elsevier Science
Year: 2002
Tongue: English
Weight: 65 KB
Volume: 109
Category: Article
ISSN: 0161-6420
DOI: 10.1016/s0161-6420(02)00989-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized comparisons of weekly versus

Randomized comparisons of weekly versus every-3-week nab-paclitaxelin patients with metastatic breast cancer

✍ J. O'Shauqhnessv; M. Lichinitser; S. Tjulandin; N. Davidson; H. Shaw; P. Bhar; W 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Randomized comparison of nab-paclitaxel

Randomized comparison of nab-paclitaxel weekly or every 3 weeks compared to docetaxel every 3 weeks as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

✍ W. Gradishar; D. Krasnojon; S. Cheporov; A. Makhson; G. Manikhas; A. Clawson; P. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Comparison of weekly and every-3-week na

Comparison of weekly and every-3-week nab-paclitaxel in elderly patients with metastatic breast cancer

✍ M. Aapro; S. Tjulandin; P. Bhar; W. Gradishar 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Phase 3 study comparing the use of docet

Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer

✍ Edgardo Rivera; Jaime A. Mejia; Banu K. Arun; Rosnie B. Adinin; Ronald S. Walter 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 120 KB 👁 1 views

## Abstract ## BACKGROUND Previous studies have evaluated 3‐week and weekly docetaxel schedules in patients with metastatic breast cancer (MBC). The varying efficacy results and toxicity profiles noted in these earlier studies led to a comparison of the schedules to determine which was safer and m

Phase II randomized trial of weekly and

Phase II randomized trial of weekly and every-3-week ixabepilone in metastatic breast cancer patients

✍ Smith, John W.; Vukelja, Svetislava; Rabe, Amy; Wentworth-Hartung, Nicole; Koutr 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 402 KB

2106 POSTER Randomized clinical comparis

2106 POSTER Randomized clinical comparison of weekly or every-3-week 130-nanometer albumin-bound paclitaxel vs. every-3-week docetaxel as first-line therapy in patients with metastatic breast cancer

✍ W.J. Gradishar; D. Krasnojon; S. Cheporov; A. Makhson; M. Georgy; A. Clawson; M. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB